Omeros stock analysis
Omeros (0KBU) Share Price & Analysis
0KBU Stock Chart & Stats
- Day’s Range
- $12.77 - $15.53
- 52-Week Range
- $6.86 - $21.48
- Previous Close
- $17.16
- Volume
- N/A
- Average Volume (3M)
- 2,432
- Market Cap
- $1.04B
- Enterprise Value
- $1.59B
- Total Cash (Recent Filing)
- $131.95M
- Total Debt (Recent Filing)
- $83.77M
- Price to Earnings (P/E)
- 8.8
- Beta
- -0.02
- Next Earnings
- Apr 05, 2027 (Est.)
- EPS Estimate
- 0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
YARTEMLEA Commercial Growth
Rapid growth in YARTEMLEA sales across consecutive quarters indicates that the approved product is gaining commercial traction. Continued revenue momentum can improve operating leverage, support investment in the pipeline, and provide a more durable foundation than collaboration income alone.
Broadening Market Adoption
Expansion across transplant-center accounts and purchasing committees strengthens the product's commercial position and increases the potential prescriber and institution base. High penetration among leading centers may support durable adoption as clinical familiarity and institutional access continue to build.
Reimbursement Protection
Favorable reimbursement mechanisms improve the product's economic value for eligible hospitals and protect reimbursement levels over the medium term. NTAP, pass-through status, and ASP-based payment can support uptake and preserve commercial incentives while adoption expands.
Bears Say
Negative Equity And Weak Cash Flow
Negative shareholder equity and sustained cash outflows indicate limited financial flexibility despite recent commercial progress. This capital structure can constrain internally funded investment, increase dependence on financing or transactions, and make the business less resilient if operating cash generation weakens.
European Regulatory Setback
The negative European regulatory opinion removes or delays a potential regional commercialization path for narsoplimab and weakens the near-term breadth of the product opportunity. It also demonstrates that regulatory approval risk remains material for the company's development-led pipeline.
Rising Gross-to-net Deductions
Higher gross-to-net deductions reduce the revenue retained from each dollar of reported gross sales, potentially limiting margin conversion as outpatient and 340B utilization grows. If deductions approach the high teens, commercial expansion may translate into less net revenue than headline sales suggest.
Omeros News
0KBU FAQ
What was Omeros’s price range in the past 12 months?
What is Omeros’s market cap?
When is Omeros’s upcoming earnings report date?
How were Omeros’s earnings last quarter?
Is Omeros overvalued?
Does Omeros pay dividends?
What is Omeros’s EPS estimate?
How many shares outstanding does Omeros have?
What happened to Omeros’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Omeros?
What is the TipRanks Smart Score and how is it calculated?
Omeros Stock Smart Score
Company Description
Omeros
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gregory A. Demopulos
- Employees
- 175
- Website
- www.omeros.com
- Address
- The Omeros Building, Seattle, WA, 98119, US
Omeros (0KBU) Earnings & Revenues
0KBU Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, led by rapid YARTEMLEA sales growth, expanding account and P&T adoption, positive operating cash flow, improved adjusted earnings, reimbursement advantages, and progress across multiple pipeline programs. The main negatives were the European regulatory setback, the OMS527 timing delay, higher expected operating expenses, and a large GAAP loss caused by noncash mark-to-market adjustments. Management repeatedly characterized commercial momentum and the company's financial position as strong.
View all GB:0KBU earnings summaries0KBU Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 1 | 0 | 11 |











